AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35895362 — intervention group
Group type: COMPARATOR
Intervention: 7-day course of amoxicillin
Number of subjects: 0
Study 33495853 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 222
Study 33495853 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 222
Study 33495853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 222
Study 33495853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 33495853 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (not specified as I or C)
Number of subjects: 222
Study 34648187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 0.3 mg/kg every 3 weeks
Number of subjects: 1000
Study 34648187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 4 weeks
Number of subjects: 1000
Study 34648187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg every 8 weeks
Number of subjects: 1000
Study 34648187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 6 weeks
Number of subjects: 1000
Study 34767573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy self-testing obtained from a pharmacy
Number of subjects: 0
Study 34767573 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status, partner's education level, travel time to MCH clinic
Number of subjects: 0
Study 34767573 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-use of pregnancy self-tests
Number of subjects: 0
Study 35237844 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR alert for cardiovascular disease and stroke risk management
Number of subjects: 7190
Study 35237844 — intervention group
Group type: COMPARATOR
Intervention: Usual EHR usage (control group)
Number of subjects: 7190
Study 32833479 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + App-Based Mindfulness Training (Unwinding Anxiety app)
Number of subjects: 80
Study 32833479 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 80
Study 36939661 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial shunt procedure
Number of subjects: 626
Study 36939661 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 626
Study 33768603 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 198
Study 33768603 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine 5 mg
Number of subjects: 198
Study 33768603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 34179941 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D high resolution stress CMR (spatial resolution 1.2 mm2)
Number of subjects: 38
Study 34179941 — intervention group
Group type: COMPARATOR
Intervention: 3D whole heart stress CMR (in-plane spatial resolution 2.3 mm2)
Number of subjects: 38
Study 34179941 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D high resolution vs. 3D whole heart
Number of subjects: 38
Study 33752431 — intervention group
Group type: EXPERIMENTAL
Intervention: IV catheter with PosiFlow regulator and infusion clip
Number of subjects: 960
Study 33752431 — intervention group
Group type: COMPARATOR
Intervention: IV catheter with infusion clip
Number of subjects: 960
Study 33752431 — intervention group
Group type: EXPERIMENTAL
Intervention: IV catheter without infusion clip
Number of subjects: 960
Study 33752431 — intervention group
Group type: EXPERIMENTAL
Intervention: IV catheter with PosiFlow regulator
Number of subjects: 960
Study 35042081 — intervention group
Group type: EXPERIMENTAL
Intervention: V591 (1×105 TCID50)
Number of subjects: 263
Study 35042081 — intervention group
Group type: EXPERIMENTAL
Intervention: V591 (1×106 TCID50)
Number of subjects: 263
Study 35042081 — intervention group
Group type: EXPERIMENTAL
Intervention: V591 (1×107 TCID50)
Number of subjects: 263
Study 35042081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 32493344 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg)
Number of subjects: 31
Study 32493344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 33175980 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min Yoga Nidra plus 60‐min lying quietly
Number of subjects: 22
Study 33175980 — intervention group
Group type: COMPARATOR
Intervention: 90‐min lying quietly
Number of subjects: 22
Study 33175980 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported mood and anxiety
Number of subjects: 22
Study 615261555 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 615261555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36343870 — intervention group
Group type: EXPERIMENTAL
Intervention: AM exercise (8:00–10:00)
Number of subjects: 45
Study 36343870 — intervention group
Group type: EXPERIMENTAL
Intervention: PM exercise (17:00–19:00)
Number of subjects: 45
Study 33876883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (1 × 10^7 cells/kg)
Number of subjects: 66
Study 33876883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32697510 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (3×5 min, 3×7 min, 3×10 min, or 3×5 min + 2×10 min in nonresponders)
Number of subjects: 180
Study 32697510 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 180
Study 32697510 — intervention group
Group type: COMPARATOR
Intervention: Sham-remote ischemic preconditioning (control)
Number of subjects: 180
Study 35511285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ash‐Kardeh (250 g daily for 6 weeks)
Number of subjects: 46
Study 34229057 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 219
Study 34229057 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 219
Study 35151397 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion plus usual care
Number of subjects: 9785
Study 35151397 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 9785
Study 35151397 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab plus usual care
Number of subjects: 9785
Study 33761625 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin for 3 months
Number of subjects: 0
Study 33761625 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 3 months
Number of subjects: 0
Study 32448089 — intervention group
Group type: EXPERIMENTAL
Intervention: direct endovascular treatment
Number of subjects: 194
Study 32448089 — intervention group
Group type: COMPARATOR
Intervention: bridging therapy (intravenous recombinant tissue-type plasminogen activator)
Number of subjects: 194
Study 35368914 — intervention group
Group type: EXPERIMENTAL
Intervention: Human adipose derived mesenchymal stem cells treatment for each 10 cm² of wound
Number of subjects: 346
Study 35368914 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing with normal saline for each 10 cm² of wound
Number of subjects: 346
Study 32372176 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous testosterone pellet
Number of subjects: 0
Study 32372176 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical testosterone gel
Number of subjects: 0
Study 32372176 — intervention group
Group type: COMPARATOR
Intervention: Placebo pellet
Number of subjects: 0
Study 32372176 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 33629920 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention during infancy
Number of subjects: 165
Study 33629920 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 165
Study 33629920 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-Morbidity profile
Number of subjects: 165
Study 33629920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Morbidity profile
Number of subjects: 165
Study 32808403 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS and rehabilitation with complex walking tasks
Number of subjects: 0
Study 32808403 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and rehabilitation with complex walking tasks
Number of subjects: 0
Study 32808403 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and rehabilitation with typical walking
Number of subjects: 0
Study 34709659 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT intervention (GNS-facilitated multidisciplinary team)
Number of subjects: 400
Study 34709659 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 34709659 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT intervention
Number of subjects: 400
Study 36510155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education programme with high content of prebiotics and probiotics (dairy and fermented foods, green leafy vegetables, high-fibre fruit, whole grains, etc.)
Number of subjects: 50
Study 36510155 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietary counselling
Number of subjects: 50
Study 32957748 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 293
Study 35963491 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Symptoms cluster (high psychosocial scores, moderate PPT)
Number of subjects: 228
Study 35963491 — intervention group
Group type: COMPARATOR
Intervention: Adaptive cluster (low psychosocial scores, high PPT)
Number of subjects: 228
Study 35963491 — intervention group
Group type: COMPARATOR
Intervention: Pain Sensitive cluster (moderate psychosocial scores, low PPT)
Number of subjects: 228
Study 32998837 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week online oral anticoagulant counseling training
Number of subjects: 33
Study 32998837 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention quality of counseling
Number of subjects: 33
Study 35535023 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-based stereotype threat (ABST)
Number of subjects: 49
Study 35535023 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 32568367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU daily for 12 months)
Number of subjects: 289
Study 32568367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diluent, daily for 12 months)
Number of subjects: 289
Study 34001750 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose (MTD) containers
Number of subjects: 173
Study 34001750 — intervention group
Group type: COMPARATOR
Intervention: Single-dose (SGD) containers
Number of subjects: 173
Study 34001750 — intervention group
Group type: COMPARATOR
Intervention: SGD instillation
Number of subjects: 173
Study 33757615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Activity Program (TAP)
Number of subjects: 250
Study 33757615 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 250
Study 33757615 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP
Number of subjects: 250
Study 35109430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalizing Imagery Therapy (MIT)
Number of subjects: 12
Study 32289673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 sessions, 4-week course of 20 Hz rTMS targeting dorsolateral prefrontal cortex at 90% RMT)
Number of subjects: 40
Study 32289673 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study 36054285 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized allogeneic bone blocks (CABB group)
Number of subjects: 24
Study 36054285 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone blocks (ABB group)
Number of subjects: 24
Study 33831950 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) - 2 days per week, 500 kcal (2100 kJ)
Number of subjects: 121
Study 33831950 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) - daily, 1500 kcal (6000 kJ)
Number of subjects: 121
Study 33831950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IER and CER
Number of subjects: 121
Study 35545816 — intervention group
Group type: EXPERIMENTAL
Intervention: ZFR00V IOLs
Number of subjects: 150
Study 35545816 — intervention group
Group type: COMPARATOR
Intervention: TFNT00 IOLs
Number of subjects: 150
Study 32447618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-ultrasound-guided dry-weight reduction
Number of subjects: 71
Study 32447618 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 71
Study 35210082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker
Number of subjects: 115
Study 35210082 — intervention group
Group type: COMPARATOR
Intervention: ICM
Number of subjects: 115
Study 32640097 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Anesthetic Device (VAD) during mesotherapy
Number of subjects: 30
Study 32640097 — intervention group
Group type: COMPARATOR
Intervention: No Vibration Anesthetic Device (Control) during mesotherapy
Number of subjects: 30
Study 35175346 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserved message (text stating 'a flu shot has been reserved for you')
Number of subjects: 11188
Study 35175346 — intervention group
Group type: EXPERIMENTAL
Intervention: Available message (text stating 'flu shots will be available')
Number of subjects: 11188
Study 35175346 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserved message
Number of subjects: 11188
Study 35175346 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who replied Y
Number of subjects: 11188
Study 35175346 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no message)
Number of subjects: 11188
Study 34135047 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultations for EMA
Number of subjects: 1222
Study 34135047 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultations for EMA
Number of subjects: 1222
Study 32798022 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly panitumumab + chemoradiotherapy during induction
Number of subjects: 126
Study 32798022 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone during induction
Number of subjects: 126
Study 32798022 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic resection
Number of subjects: 126
Study 32798022 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive resections
Number of subjects: 126
Study 32798022 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical adverse events
Number of subjects: 126
Study 32798022 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day mortality
Number of subjects: 126
Study 32798022 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day mortality
Number of subjects: 126
Study 32798022 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 126
Study 35178117 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined nursing management methods
Number of subjects: 0
Study 35178117 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing management methods
Number of subjects: 0
Study 33651091 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (15 μg/m2/d for 4 weeks, continuous intravenous infusion)
Number of subjects: 108
Study 33651091 — intervention group
Group type: COMPARATOR
Intervention: Consolidation chemotherapy
Number of subjects: 108
Study 33651091 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 108
Study 36455168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg)
Number of subjects: 453
Study 36455168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study 34248023 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared‐assisted total thyroidectomy with indocyanine green (ICG) angiography
Number of subjects: 58
Study 34248023 — intervention group
Group type: COMPARATOR
Intervention: Standard total thyroidectomy
Number of subjects: 58
Study 32032355 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic test for lifetime risk of prostate cancer (based on genotyping of 33 risk‐associated single nucleotide polymorphisms) in intervention practices.
Number of subjects: 7800
Study 32032355 — intervention group
Group type: COMPARATOR
Intervention: Standard PSA test without genetic risk assessment in control practices.
Number of subjects: 7800
Study 36383742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine
Number of subjects: 99
Study 36383742 — intervention group
Group type: COMPARATOR
Intervention: Midazolam placebo
Number of subjects: 99
Study 36383742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral benzodiazepines (considered as a binary predictor)
Number of subjects: 99
Study 36383742 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral benzodiazepines (considered as a continuous predictor)
Number of subjects: 99
Study 32578850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily for 12 months
Number of subjects: 66
Study 32578850 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 66
Study 35407540 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up by a cardiologist and a geriatrician (intervention)
Number of subjects: 150
Study 35407540 — intervention group
Group type: COMPARATOR
Intervention: Usual care by a cardiologist (control)
Number of subjects: 150
Study 35407540 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hospitalization
Number of subjects: 150
Study 35407540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 150
Study 32845087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dissonance-based weight stigma intervention
Number of subjects: 156
Study 32845087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 34800700 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus immunotherapy (durvalumab plus tremelimumab)
Number of subjects: 301
Study 34800700 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy (durvalumab plus tremelimumab)
Number of subjects: 301
Study 33314886 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein supplement (2:2 ratio)
Number of subjects: 8
Study 33314886 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-protein supplement (3:1 ratio)
Number of subjects: 8
Study 33314886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 32790701 — intervention group
Group type: EXPERIMENTAL
Intervention: cfPWV
Number of subjects: 6734
Study 32790701 — intervention group
Group type: EXPERIMENTAL
Intervention: baPWV
Number of subjects: 6734
Study 32790701 — intervention group
Group type: EXPERIMENTAL
Intervention: bfPWV
Number of subjects: 6734
Study 35940551 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention including five group education sessions on DMII and HTN management and two one-on-one goal setting sessions.
Number of subjects: 195
Study 35940551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 195
Study 33351701 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 86
Study 35685538 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron (Group O)
Number of subjects: 55
Study 35685538 — intervention group
Group type: COMPARATOR
Intervention: 2 mL saline (Group S)
Number of subjects: 55
Study 34992867 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin chemotherapy (40 mg/m2/cycle, 5 cycles)
Number of subjects: 212
Study 34992867 — intervention group
Group type: COMPARATOR
Intervention: Three weekly cisplatin chemotherapy (100 mg/m2/cycle, 2 cycles)
Number of subjects: 212
Study 34581459 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual neuropsychological intervention
Number of subjects: 120
Study 34581459 — intervention group
Group type: EXPERIMENTAL
Intervention: Group neuropsychological intervention
Number of subjects: 120
Study 34581459 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 120
Study 34581459 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (individual and group)
Number of subjects: 120
Study 32534369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and azithromycin (first-choice treatment)
Number of subjects: 0
Study 32534369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and azithromycin
Number of subjects: 0
Study 32534369 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine or chloroquine
Number of subjects: 0
Study 35799258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary Behaviour Intervention (SB-I)
Number of subjects: 267
Study 35799258 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity + Sedentary Behaviour Intervention (PA + SB-I)
Number of subjects: 267
Study 35799258 — intervention group
Group type: COMPARATOR
Intervention: Usual Practice (Control)
Number of subjects: 267
Study 35799258 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention (PA-I)
Number of subjects: 267
Study 32517497 — intervention group
Group type: EXPERIMENTAL
Intervention: Icare rebound tonometer
Number of subjects: 1266
Study 32517497 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer
Number of subjects: 1266
Study 36315419 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Number of subjects: 239
Study 36315419 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 239
Study 33845980 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate arithmetic training
Number of subjects: 0
Study 33845980 — intervention group
Group type: COMPARATOR
Intervention: Visuo-spatial working memory training
Number of subjects: 0
Study 32750502 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront combination therapy with fluoropyrimidine (FP), irinotecan (Iri), and bevacizumab (Bev)
Number of subjects: 421
Study 32750502 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment with FP and Bev followed by escalation to Iri, FP, and Bev
Number of subjects: 421
Study 35180284 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in dietary vitamin K intake (median 194.4 μg/d)
Number of subjects: 5533